Trials / Completed
CompletedNCT00766545
Cilostazol Stroke Prevention Study : A Placebo-controlled Double-blind Trial for Secondary Prevention of Cerebral Infarction.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1,095 (actual)
- Sponsor
- Otsuka Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 20 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The multi-center, double-blind, placebo-controlled, randomized, group-comparison study was designated to assess the long-term safety and efficacy of the antiplatelet drug cilostazol in preventing the recurrence of cerebral infarction in patients who had suffered a cerebral infarction 1 to 6 months prior to entering the trial.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | cilostazol | oral tablet 100 mg, twice daily, over 1 year |
| DRUG | placebo of cilostazol | oral tablet, 0 mg twice daily, over 1 year |
Timeline
- Start date
- 1992-04-01
- Primary completion
- 1997-03-01
- Completion
- 1997-03-01
- First posted
- 2008-10-06
- Last updated
- 2021-03-01
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT00766545. Inclusion in this directory is not an endorsement.